Goserelin vs Leuprolide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicGoserelinLeuprolide
What it is

A synthetic decapeptide analogue of GnRH that, with continued use, suppresses the pituitary’s release of reproductive hormones, according to the label.1

A GnRH agonist. The Eligard label describes leuprolide acetate as a synthetic nonapeptide analogue of GnRH that is more potent than the natural hormone.3

FDA status

FDA-approved

FDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis1,2

FDA-approved. Drugs@FDA lists Zoladex with an original approval date of December 29, 1989. The cited label has no boxed warning.1,2

Is goserelin FDA-approved?

FDA-approved

FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products3,4,5,6,7,8

FDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and Eligard with one of January 23, 2002, among many leuprolide applications. The cited Eligard label has no boxed warning.3,4,6

Is leuprolide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.9

Not among the six peptides the policy lists.9

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Controlled human trial A multicenter, controlled trial in 466 men with prostate cancer confined to the pelvis comparing Zoladex plus flutamide and radiation with radiation alone, described in the label as a basis of its prostate cancer indication.1
  • Large randomized human trial Trial 0022: a double-blind, randomized, placebo-controlled trial in 358 participants, premenopausal women with abnormal uterine bleeding before endometrial ablation, described in the label as a basis of that indication.1
  • Controlled human trial Controlled trials comparing Zoladex with danazol in endometriosis and a randomized trial comparing it with removal of the ovaries in breast cancer, described in the label.1

Limited human data

  • Small, short, or incompletely reported human study Four open-label studies described in the Eligard label, one for each of its formulations, in 120, 117, 90 and 111 men with prostate cancer, with suppression of testosterone to castrate levels as the main measure.3
Records collected

30 ClinicalTrials.gov records and 30 PubMed records collected

117 ClinicalTrials.gov records and 48 PubMed records collected

Area of study

Hormones, Sexual and reproductive health, Cancer1

Sexual and reproductive health, Cancer

Latest dated events
  1. DailyMed publishes the Zoladex label version cited on this page.1
  2. FDA approves Zoladex, according to Drugs@FDA.2
  1. FDA approves Vobrig for central precocious puberty in children.7,8
  2. DailyMed publishes the Eligard label version cited on this page.3
  3. FDA approves Fensolvi, according to Drugs@FDA.10

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ZOLADEX (goserelin) implant · SPL version 9 · published 2026-03-26 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: ZOLADEX (goserelin acetate), NDA 019726 · original approval December 29, 1989 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked November 15, 2026

  9. 9
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  10. 10
    Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026